Aridica Corporation
Aridica Corporation is dedicated to advancing immune system research and clinical applications by providing high-quality, automated immune cell isolation solutions. Their mission is to accelerate the development of diagnostics and next-generation therapeutics by simplifying and standardizing the process of immune cell separation. With a focus on automation, reliability, scalability, and sustainability, Aridica aims to empower researchers and clinicians to unlock the full potential of the immune system for improved health outcomes.
Aridica Corporation is currently seeking investment
Aridica Corporation is seeking a seed investment in the range of 1m-5m
What We Do
A fully automated platform for the separation of peripheral blood mononuclear cells (PBMCs) from whole blood, designed to accelerate research and development in immune-targeted diagnostics and therapeutics. The platform emphasizes consistency, reliability, and ease of use, supporting high-resolution single cell genomics, cytometry, and biomarker discovery.
Aridica offers laboratory automation tools for high-quality immune cell isolation, enabling more consistent, reliable, and scalable sample preparation for research and clinical applications. Their technology reduces operator variability, minimizes sample handling, saves time, and reduces waste, making immune cell isolation easier and more reproducible across labs and over time.
Application Area
Digital Health Technologies
Key People
News & Updates
Recognized as one of the most promising innovators in life science tools and diagnostics, Aridica was selected for the prestigious BioTools Innovator Accelerator program, joining a top-tier global cohort.
Awarded $238,000 by the Colorado OEDIT Advanced Industries Accelerator program to advance the development of their blood separation technology.
Aridica was chosen from over 400 applicants as one of 31 startups to join the 2025 BioTools Innovator Accelerator, a global program for life science tools and diagnostics companies. The program offers mentorship, investor exposure, and the opportunity to compete for $300,000 in non-dilutive cash prizes. Aridica will participate in events such as the Innovator Summit and Capstone Event.
Aridica was awarded a $238,000 Early-Stage Capital and Retention grant from the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Accelerator program. The grant supports the development, prototyping, and testing of Aridica’s blood separation technology, preparing the company for commercialization and growth in Colorado.